U.S. Markets open in 5 hrs 8 mins

Opko Health, Inc. (OPK)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.48+0.15 (+2.37%)
At close: 4:00PM EDT
People also watch
CLDXACADSRPTHZNPINO

Opko Health, Inc.

4400 Biscayne Boulevard
Miami, FL 33137
United States
305-575-4100
http://www.opko.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees6,041

Key Executives

NameTitlePayExercisedAge
Dr. Philip Frost M.D., Ph.D.Chairman & CEO970.6kN/A78
Dr. Jane H. Hsiao Ph.D., MBAVice Chairman and Chief Technical Officer970.6kN/A70
Mr. Adam E. LogalChief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer610.6kN/A39
Mr. Steven D. Rubin J.D., Esq.Exec. VP of Admin. and Director820.6k2.29M57
Ms. Kate Inman Esq.Deputy Gen. Counsel and Sec.N/AN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Corporate Governance

Opko Health, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.